1. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: A single-centre, randomized, controlled trial;Abbaspour Kasgari;The Journal of Antimicrobial Chemotherapy,2020
2. Design of a multiepitope-based peptide vaccine against the E protein of human COVID-19: An immunoinformatics approach;Abdelmageed;BioMed Research International,2020
3. ACTIV-3. Therapeutics for inpatients with COVID-19 (TICO). NCT04501978. . Accessed 10.03.21.
4. Ad26.COV2-S FDA Approval Status. . Accessed 30.08.21.
5. A dose-confirmation study to evaluate the safety, reactogenicity and immunogenicity of vaccine CVnCoV in healthy adults for COVID-19. . Accessed 19.03.21.